Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Characterization of the contractile P2Y14 receptor in mouse coronary and cerebral arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Structure of a dimeric fungal α-type carbonic anhydrase

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. AKAP 18 alpha and gamma have opposing effects on insulin release in INS-1E cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Random mutagenesis of human topoisomerase II alpha cDNA followed by functional expression in yeast cells lacking endogenous topoisomerase II activity in the presence of ICRF-187, identified five functional mutations conferring cellular bisdioxopiperazine resistance. The mutations L169F, G551S, P592L, D645N, and T996L confer > 37, 37, 18, 14, and 19 fold resistance towards ICRF-187 in a 24 h clonogenic assay, respectively. Purified recombinant L169F protein is highly resistant towards catalytic inhibition by ICRF-187 in vitro while G551S, D645N, and T996L proteins are not. This demonstrates that cellular bisdioxopiperazine resistance can result from at least two classes of mutations in topoisomerase II; one class renders the protein non-responsive to bisdioxopiperazine compounds, while an other class does not appear to affect the catalytic sensitivity towards these drugs. In addition, our results indicate that different protein domains are involved in mediating the effect of bisdioxopiperazine compounds.

OriginalsprogEngelsk
TidsskriftFEBS Letters
Vol/bind480
Udgave nummer2-3
Sider (fra-til)201-7
Antal sider7
ISSN0014-5793
DOI
StatusUdgivet - 1 sep. 2000

ID: 59178699